Carcinoid Tumor Epidemiology Forecast to 2030 by DelveInsight

Carcinoid Tumor Epidemiology Forecast to 2030 by DelveInsight

DelveInsight has launched a new report on Carcinoid Tumor Epidemiology

Carcinoid tumors (CT) are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon, and rectum) or in the lungs.

Request for free sample copy-

The Carcinoid Tumor Epidemiology report covers a descriptive overview of the Carcinoid Tumor, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Carcinoid Tumor and its treatment in the 7MM, covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan

Carcinoid Tumor Epidemiology

CT most commonly develops in the gastrointestinal tract. However, they can also occur in other parts of the body such as the lungs, ovaries, or testicles. Based on the location and size of the tumor, CT usually presents with the subset of the symptoms such as cutaneous flushing, itching, and palpitation, edema, salivation, upper body erythema, chronic diarrhea, malabsorption, and breathing difficulties, etc. Till now, the associated causes of CT remains largely unknown, however common risk factors includes getting affected with disorders, such as multiple endocrine neoplasia, pernicious anemia, or Zollinger-Ellison syndrome, etc.

Key facts of the Carcinoid Tumor Epidemiology report

  • Literature studies suggest that women are more likely to develop carcinoid tumors than men.
  • As per the study conducted by Siddiqui et al. titled “The Epidemiology of Carcinoid Tumors of Small and Large Intestine in USA: A National Inpatient Sample Analysis” the malignant CTs of small intestine were the most common out of all CTs of intestine. Interestingly there was male predominance in CTs of small intestine and female predominance in CTs of large intestine.
  • According to a study by Taal et al. titled “Epidemiology of Neuroendocrine Tumours”, the reported incidence of neuroendocrine tumors was approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites were the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%.
  • The National Organization for Rare Disorders estimates that 27 new cases of Carcinoid Tumour per million are diagnosed in the United States per year out of which, only about 10% develops carcinoid syndrome.
  • According to the study titled “Carcinoid syndrome” conducted by Rehman et al., in Japan, the rate of incidence of carcinoid tumors was 5.25 cases per 100,000 in 2004.

Carcinoid Tumor Epidemiology Segmentation

  • Total Incident Population of Carcinoid Tumor (2017-2030)
  • Gender-specific Incident Population of Carcinoid Tumor (2017-2030)
  • Origin-specific Incident Population of Carcinoid Tumor (2017-2030)
  • Incident Population of Carcinoid Tumor (2017-2030)
  • Incident Population of Carcinoid Tumor (2017-2030)

Carcinoid Tumor Epidemiology Key Strengths

  • 11 year forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Sub-type Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

What will be the key questions answered?

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Carcinoid Tumor?
  • What are the key findings pertaining to the Carcinoid Tumor epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Carcinoid Tumor across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Carcinoid Tumor?
  • What are the currently available treatments of Carcinoid Tumor?

Request for free sample copy-

Table of content

1. Key Insights 

2. Executive Summary of Carcinoid Tumor

3. Carcinoid Tumor: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight


Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global Carcinoid Tumor market
  • Quantify patient populations in the global Carcinoid Tumor market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Carcinoid Tumor therapeutics in each of the markets covered
  • Understand the magnitude of Carcinoid Tumor population by its epidemiology
  • The Carcinoid Tumor Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Related Reports


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States